Glucagon receptor antagonist LY2409021 + Placebo
Pre-clinicalUNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes After Total Pancreatectomy
Conditions
Diabetes After Total Pancreatectomy
Trial Timeline
Apr 1, 2016 → Jul 1, 2021
NCT ID
NCT02944110About Glucagon receptor antagonist LY2409021 + Placebo
Glucagon receptor antagonist LY2409021 + Placebo is a pre-clinical stage product being developed by Eli Lilly for Diabetes After Total Pancreatectomy. The current trial status is unknown. This product is registered under clinical trial identifier NCT02944110. Target conditions include Diabetes After Total Pancreatectomy.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes After Total Pancreatectomy were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
3
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02944110 | Pre-clinical | UNKNOWN |
Competing Products
20 competing products in Diabetes After Total Pancreatectomy